疫苗适龄女性高级别宫颈病变中的HPV疫苗接种错过机会
本研究基于美国康涅狄格州2008–2015年CIN2+监测数据,分析疫苗适龄女性未接种HPV疫苗的原因及影响因素。1625名疫苗适龄CIN2+女性中882人从未接种,未接种比例无显著变化;常见原因包括年龄过大、既往HPV诊断和无医生推荐,公共或未保险者更可能未接种。
要点
- 疫苗适龄CIN2+女性中未接种HPV疫苗比例高且2008–2015年无显著下降。
- 常见未接种原因(年龄过大、既往HPV诊断)并非接种禁忌。
- 无医生推荐是重要障碍,公共/无保险者更易未接种。
核心结论
- 疫苗适龄女性中HPV疫苗接种错过机会普遍,未接种比例在2008–2015年间无显著变化(p=0.18,范围49.1%至60.0%)。
研究设计与样本
- 基于康涅狄格州2008–2015年CIN2+全州监测系统,对纽黑文县居民通过病历审查和患者访谈收集增强监测数据。
- 纳入1625名疫苗适龄CIN2+女性,其中882人报告从未接种HPV疫苗。
- 采用双侧Cochran Armitage趋势检验分析未接种原因趋势,对数二项分析评估社会人口学特征与接种状态的关联。
主要发现
- 2008–2015年共1625名疫苗适龄女性诊断为CIN2+,882人报告从未接种HPV疫苗。
- 未接种疫苗适龄女性比例从2008至2015年无显著变化(p=0.18,范围49.1%至60.0%)。
- 最常报告的未接种原因为年龄过大,其次为既往HPV诊断和无医生推荐。
- 公共保险或无保险女性比私人保险女性更可能报告未接种(p=<0.001,p=0.0034)。
临床怎么用
- 医生应主动向所有疫苗适龄患者推荐HPV疫苗,消除年龄过大和既往HPV诊断等错误观念。
- 关注公共保险或无保险女性的接种障碍,加强免疫促进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Incidence of high-grade cervical lesions (HGCL) has declined in the U.S following the introduction of the human papillomavirus (HPV) vaccine in 2006. However, many women continue to be diagnosed with HGCLs, including those eligible to receive the vaccine but did not. We determined self-reported barriers to and correlates of HPV vaccination in vaccine-eligible women diagnosed with cervical intraepithelial neoplasia grades 2, 2/3, 3 and adenocarcinoma in situ (CIN2+). METHODS: Data from a statewide surveillance system in Connecticut for CIN 2+ during 2008-2015 were used for this analysis. Enhanced surveillance data were collected for women residing in New Haven County, including HPV vaccine history and demographic factors, through chart review and patient interviews. Women who reported being unvaccinated were asked why they did not receive the vaccine. We evaluated trends in reasons for not receiving the vaccine using a two-sided Cochran Armitage trend test. Log-binomial analysis was used to assess associations between sociodemographic characteristics and vaccination status. RESULTS: Between 2008 and 2015, 1625 vaccine-eligible women were diagnosed with CIN2+, with 882 of these women reporting never receiving the HPV vaccine. The proportion of unvaccinated vaccine-eligible women did not significantly change from 2008 to 2015 (p = 0.18, range 49.1% to 60.0%). The most commonly reported reason for being unvaccinated was age/too old, followed by previous HPV diagnosis and no provider recommendation. Women who had public or no insurance were significantly more likely than privately insured women to report being unvaccinated (p = <0.001, p = 0.0034). CONCLUSIONS: Commonly cited barriers to vaccination, such as age/too old and previous HPV diagnosis, are not contraindications for vaccination. Furthermore, frequent reporting of no provider recommendation underscores the important role providers play in the immunization of their patients. These results indicate the need for greater efforts by providers to dispel myths about HPV vaccine eligibility and to promote vaccination for all of their eligible patients.
引用
- Russ SM, Brackney M, Meek J, et al. Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions. Vaccine. 2019. PMID: 31248688. doi:10.1016/j.vaccine.2019.06.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。